HUP0202192A3 - Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof - Google Patents

Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof

Info

Publication number
HUP0202192A3
HUP0202192A3 HU0202192A HUP0202192A HUP0202192A3 HU P0202192 A3 HUP0202192 A3 HU P0202192A3 HU 0202192 A HU0202192 A HU 0202192A HU P0202192 A HUP0202192 A HU P0202192A HU P0202192 A3 HUP0202192 A3 HU P0202192A3
Authority
HU
Hungary
Prior art keywords
composition
oral administration
preparing same
cefuroxime axetil
solid dispersant
Prior art date
Application number
HU0202192A
Other languages
English (en)
Original Assignee
Hanmi Pharm Co Ltd Hwaseong Gu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Co Ltd Hwaseong Gu filed Critical Hanmi Pharm Co Ltd Hwaseong Gu
Publication of HUP0202192A2 publication Critical patent/HUP0202192A2/hu
Publication of HUP0202192A3 publication Critical patent/HUP0202192A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU0202192A 1999-08-04 2000-07-25 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof HUP0202192A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990031989A KR100342943B1 (ko) 1999-08-04 1999-08-04 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Publications (2)

Publication Number Publication Date
HUP0202192A2 HUP0202192A2 (en) 2002-10-28
HUP0202192A3 true HUP0202192A3 (en) 2004-04-28

Family

ID=19606197

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202192A HUP0202192A3 (en) 1999-08-04 2000-07-25 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof

Country Status (19)

Country Link
US (1) US6107290A (hu)
EP (1) EP1080721B1 (hu)
JP (1) JP3479244B2 (hu)
KR (1) KR100342943B1 (hu)
CN (1) CN1189161C (hu)
AT (1) ATE257010T1 (hu)
AU (1) AU769451B2 (hu)
CA (1) CA2378267A1 (hu)
CZ (1) CZ2002372A3 (hu)
DE (1) DE69913958T2 (hu)
ES (1) ES2212438T3 (hu)
HU (1) HUP0202192A3 (hu)
MX (1) MXPA02001116A (hu)
NZ (1) NZ516760A (hu)
RU (1) RU2215521C1 (hu)
SI (1) SI20747A (hu)
TR (1) TR200200287T2 (hu)
WO (1) WO2001010410A1 (hu)
YU (1) YU7502A (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
IN191496B (hu) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
KR100362230B1 (ko) * 2000-04-21 2002-11-23 주식회사 대웅제약 저융점 무정형 세푸록심 악세틸의 제조방법
WO2002043707A1 (en) * 2000-12-01 2002-06-06 Abdul Rehman Khan Pharmaceutical formulation
US6779246B2 (en) * 2001-04-23 2004-08-24 Appleton Papers Inc. Method and system for forming RF reflective pathways
US6892441B2 (en) * 2001-04-23 2005-05-17 Appleton Papers Inc. Method for forming electrically conductive pathways
OA12625A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
TW200403075A (en) * 2002-05-29 2004-03-01 Akzo Nobel Nv Progestagenic dosage units
KR100523082B1 (ko) * 2002-09-11 2005-10-20 (주)다산메디켐 쓴 맛이 은폐된 세푸록심악세틸 제제의 제약조성물 및 그의 제조방법
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
CA2532931A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
ES2379631T3 (es) * 2003-10-08 2012-04-30 Meiji Seika Pharma Co., Ltd. Composición antibacteriana no cristalina que contiene cefditoren pivoxilo
JP2007517864A (ja) * 2004-01-09 2007-07-05 ハンミ ファーム． シーオー．， エルティーディー． セフロキシムアキセチル顆粒及びこの製造方法
KR100801589B1 (ko) 2004-01-09 2008-02-05 한미약품 주식회사 세푸록심 악세틸 과립 및 이의 제조방법
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
JP5893461B2 (ja) 2011-04-07 2016-03-23 日産自動車株式会社 位置検出装置および位置検出方法
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
TWI586379B (zh) 2015-06-29 2017-06-11 永信藥品工業股份有限公司 一種製作難溶藥物固體劑型的方法
CN116284050B (zh) * 2022-12-19 2024-04-12 华北制药河北华民药业有限责任公司 一种高效率结晶型头孢呋辛酯转无定型粉体的方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
IN186539B (hu) * 1997-09-29 2001-09-29 Ranbaxy Lab Ltd
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
ATE257010T1 (de) 2004-01-15
DE69913958T2 (de) 2004-06-09
YU7502A (sh) 2004-09-03
US6107290A (en) 2000-08-22
HUP0202192A2 (en) 2002-10-28
CN1367683A (zh) 2002-09-04
CA2378267A1 (en) 2001-02-15
KR20010016826A (ko) 2001-03-05
EP1080721A3 (en) 2001-05-02
TR200200287T2 (tr) 2002-07-22
EP1080721A2 (en) 2001-03-07
RU2215521C1 (ru) 2003-11-10
DE69913958D1 (de) 2004-02-05
JP2001048777A (ja) 2001-02-20
AU5855100A (en) 2001-03-05
WO2001010410A1 (en) 2001-02-15
CN1189161C (zh) 2005-02-16
KR100342943B1 (ko) 2002-07-02
NZ516760A (en) 2004-01-30
SI20747A (sl) 2002-06-30
ES2212438T3 (es) 2004-07-16
AU769451B2 (en) 2004-01-29
EP1080721B1 (en) 2004-01-02
MXPA02001116A (es) 2002-08-20
CZ2002372A3 (cs) 2002-06-12
JP3479244B2 (ja) 2003-12-15

Similar Documents

Publication Publication Date Title
HUP0202192A3 (en) Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof
HUP0202100A2 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
AU4867697A (en) Oxadiazoles, processes for preparing them and their use as pharmaceutical compositions
EG24142A (en) Crystalline monohydrate, process for the preparation thereof and the use thereof for preparing a pharmaceutical composition
HUP0303524A3 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use
MXPA02012045A (es) Nuevos derivados de oxazolidinona y proceso para su preparacion.
AU6360400A (en) Ceramic dental mill blanks
HUP0103082A2 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
AU5868500A (en) Home digital assistant
HUP0203766A3 (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof and pharmaceutical compositions containing them
IL144501A0 (en) Epothilone derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
HUP0103404A3 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0104412A3 (en) Compositions comprising cefuroxime axetil and process for their preparation
PL351616A1 (en) Polyolefin compositions, method for the production and use thereof
AU7446900A (en) Thioalkylamine derivatives and process for the preparation thereof
IL147248A0 (en) Naphthyridine derivatives, process for their preparation, their use and pharmaceutical compositions comprising them
AU3825700A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
HK1046284A1 (en) Polymorphs of crystalline azabicyclo(2,2,2)octan-3-aminecitrate and their pharmaceutical compositions.
HUP0203384A3 (en) Process for the preparation of ketimines
AU2001264385A1 (en) Novel cephalosporin compounds and process for preparing the same
AU2155501A (en) Process for the preparation of ketimines
AU5524400A (en) Novel 6-amino-uracil derivatives, preparation and use thereof